# Tatva Chintan Pharma Chem share price today (Tatva Chintan Pharma Chem Ltd, NSE: TATVA)

> Tatva Chintan Pharma Chem share price today: ₹1,637.10 at the NSE close on 3 November 2026, up 15.1% in a year. Tatva Chintan Pharma Chem (NSE: TATVA) is worth ₹3,829 crore, trades at a P/E of 60.0 and has closed between ₹1,090.20 and ₹1,944.00 over the past 52 weeks. > Tatva Chintan Pharma Chem Ltd's results are improving, while its P/E is near the low end of its own history over 5.3 years, higher than only 25% of past readings. TATVA · Speciality Chemicals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/tatva-chintan-pharma-chem-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from the last 12 quarters
- Price: ₹1,637.10 (+15.1% in a year)
- P/E: 60.0× (lower than 75% of the last 5.3 years)
- Revenue (Sep 2026): ₹217 Cr (+75.0% on a year ago)
- Profit (Sep 2026): ₹21.0 Cr (+110.0% on a year ago)
- Operating margin: 19.0% (+1.0 points on a year ago)
- ROCE: 7%, FY26
- ROIC: 7.1%, against a 12.0% cost of capital: −4.9 points

The main question: yearly earnings per share moved +636.9% while the share price moved +15.1%. ## What is the Tatva Chintan Pharma Chem share price today? Tatva Chintan Pharma Chem Ltd's share price was ₹1,637.10 at the close on 3 November 2026. It has been rising for 27 weeks. That is 11.0% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row. In the last 52 weeks it traded between ₹1,090 and ₹1,944, and at that close it sat 64% of the way up from that low. Over the last 5.3 years the share price moved −28% while the NIFTY 500 moved +57%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Tatva Chintan Pharma Chem this quarter? Three changes stood out: revenue up on a year earlier for 8 quarters in a row, highest quarterly profit in 16 quarters and highest quarterly revenue in 16 quarters. 1. Revenue up on a year earlier for 8 quarters in a row In the September 2026 quarter revenue was ₹217 crore, +75% on a year earlier. 2. Highest quarterly profit in 16 quarters Profit of ₹21 crore in the September 2026 quarter is the highest of the last 16 quarters. 3. Highest quarterly revenue in 16 quarters Revenue of ₹217 crore in the September 2026 quarter is the highest of the last 16 quarters. ## What are Tatva Chintan Pharma Chem's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Tatva Chintan Pharma Chem reported revenue of ₹217 crore, up 75.0% from ₹124 crore a year earlier, and a profit of ₹21.0 crore, up 110.0% from ₹10.0 crore. ### Tatva Chintan Pharma Chem results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹217 crore | ₹124 crore | +75.0% |
| Profit | ₹21.0 crore | ₹10.0 crore | +110.0% |
| Earnings per share | ₹9.17 | ₹4.24 | +116.3% |
| Operating margin | 19.0% | 18.0% | +1.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 17 July 2026, about April to June 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Tatva Chintan Pharma Chem share price history? Tatva Chintan Pharma Chem closed at ₹1,637.10 on 3 November 2026, up 15.1% from ₹1,422.30 a year earlier (31 October 2025) and down 42.4% over five years. Its highest weekly close since July 2021 was ₹2,843.30 on 4 November 2021. ### Tatva Chintan Pharma Chem share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,569.30 | +4.3% |
| 1 month ago · 1 Oct 2026 | ₹1,743.20 | −6.1% |
| 6 months ago · 30 Apr 2026 | ₹1,311.00 | +24.9% |
| 1 year ago · 31 Oct 2025 | ₹1,422.30 | +15.1% |
| 3 years ago · 3 Nov 2023 | ₹1,422.95 | +15.0% |
| 5 years ago · 4 Nov 2021 | ₹2,843.30 | −42.4% |
| Earliest weekly close in our records · 30 Jul 2021 | ₹2,267.85 | −27.8% |
| Highest weekly close since July 2021 · 4 Nov 2021 | ₹2,843.30 | −42.4% |
| Lowest weekly close since July 2021 · 13 Mar 2025 | ₹637.00 | +157.0% |
| 52-week high (weekly close) · 16 Oct 2026 | ₹1,944.00 | −15.8% |
| 52-week low (weekly close) · 1 Feb 2026 | ₹1,090.20 | +50.2% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (282 weekly closes from 30 July 2021 to 3 November 2026.)

## What is the latest news on Tatva Chintan Pharma Chem? 3 Nov 2026: Tatva Chintan Pharma Chem closed at ₹1,637.10, up 4.3% on the week and down 6.1% on the month. Results for July to September 2026: Revenue up 75.0% and profit up 110.0% on a year earlier. ### Earlier

- 11 Sep 2026: ex-date for a dividend of ₹2 a share. - Our read, 19 Jul 2026: Tatva Chintan has transitioned from a pure Phase Transfer Catalyst (PTC) business to higher-margin pharma and agro intermediates, commissioning its Dahej block and initiating a greenfield Jolwa facility. Recent margin pressure stems from pricing lag and under-utilized capacity, but operating leverage will expand margins as peak pharma revenue commercializes. - 17 Jul 2026: Tatva Chintan Pharma Chem held its results call for April to June 2026. Management guided: FY27 consolidated revenue growth 25-30% with operating margin goal 20-22%. ### Our read of the business

Tatva Chintan has transitioned from a pure Phase Transfer Catalyst (PTC) business to higher-margin pharma and agro intermediates, commissioning its Dahej block and initiating a greenfield Jolwa facility. Recent margin pressure stems from pricing lag and under-utilized capacity, but operating leverage will expand margins as peak pharma revenue commercializes. July to September 2026: Semiconductor qualification achieved; Pharma scaling. (Our read after the July to September 2026 results, written 19 July 2026.)

## What dividend does Tatva Chintan Pharma Chem pay? Tatva Chintan Pharma Chem paid ₹2 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.12% at the ₹1,637.10 close on 3 November 2026. The last was a dividend of ₹2 a share, ex-date 11 September 2026. ### Tatva Chintan Pharma Chem dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 11 Sep 2026 | ₹2 | Dividend | same day |
| 12 Sep 2025 | ₹1 | Dividend | same day |
| 6 Sep 2024 | ₹2 | Dividend | same day |
| 8 Sep 2023 | ₹2 | Dividend | same day |
| 8 Sep 2022 | ₹2 | Dividend | 9 Sep 2022 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Tatva Chintan Pharma Chem Ltd paid out 11% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 9 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Tatva Chintan Pharma Chem management say on the latest results call? On the call for April to June 2026, held on 17 July 2026, Tatva Chintan Pharma Chem's management guided: FY27 consolidated revenue growth 25-30% with operating margin goal 20-22%. > “I am extremely proud to share that our first batch produced on commercial plant scale was delivered to the customer during this quarter. This batch has been successfully qualified by the customer. We consider this to be one of Tatva Chintan's stellar achievements of the past decade. The significance of this achievement extends far beyond a single product. …”
> Chinthan Shah, on the call for April to June 2026

### What management guided

- FY27 pharma molecules revenue ₹70-80 crores from three molecules (one commercial production Q1, two additional by Q3); full utilization potential ₹200 crore. - FY27 Electrolyte Salts revenue ₹40-60 crores (goal 10% of total revenue mix); progression dependent on raw material supply chain normalization. - New greenfield facility capital spending ₹200 crore approved by Board with groundbreaking July 20, 2026; 18-21 month operational timeline planned (management internally pushing 18-month acceleration); facility designed as fungible multi-product platform. - New facility peak revenue capacity ₹300 crore at modeled asset turnover of 1.2-1.5x. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/43550/Conference Call/CC-Jul26.pdf). (From the call for April to June 2026, 17 July 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What is the future of Tatva Chintan Pharma Chem? What is changing in the business? What is changing at Tatva Chintan Pharma Chem, from the latest results and calls: pharma commercialization ramp and semiconductor validation. - Pharma Commercialization Ramp. Three pharma molecules launching to deliver new revenue stream. ⚠ estimate
- Semiconductor Validation. Plant-scale qualification completed, opening pathway for future commercialization. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the July to September 2026 results, written 19 July 2026.)

## What could change the Tatva Chintan Pharma Chem story? What are the risks? Inability to pass through raw material cost inflation to customers within an initial lag by the third quarter, leading to operating margin remaining depressed. ### Each change stops working if

- Pharma Commercialization Ramp: Customer validation for the remaining two molecules fails or is delayed. - Semiconductor Validation: Competitor develops an alternative less-toxic chemistry before Tatva achieves full commercial scale. ### The main risks

- Raw Material Inflation: Geopolitical disruption elevating amine prices. ✓ fact
- Working Capital Drag: Inventory days expanded, suppressing operating cash flow. ✓ fact

(Our read after the July to September 2026 results, written 19 July 2026.)

## What to watch in Tatva Chintan Pharma Chem's next results? When Tatva Chintan Pharma Chem reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Electrolyte Salts quarterly progression toward ₹40-60 crore FY27 goal - track sequential ramp from Q1 base of ₹6 crore; validate raw material supply chain normalization post-Middle East crisis and confirm customer demand visibility translates to consistent quarterly ramping. - What to check (from the call)
- Electrolyte Salts quarterly progression toward ₹40-60 crore FY27 goal - track sequential ramp from Q1 base of ₹6 crore; validate raw material supply chain normalization post-Middle East crisis and confirm customer demand visibility translates to consistent quarterly ramping. - Pharma molecules revenue incrementally confirmed - validate three-molecule commercialization pathway (one live Q1, two by Q3) tracking toward cumulative ₹70-80 crore FY27 contribution with visible repeat order trends confirming customer acceptance and demand sustainability. - New greenfield facility groundbreaking execution on July 20, 2026 - binary confirmation of ₹200 crore capital spending commitment credibility and 18-21 month operational timeline feasibility; any slippage signals capital allocation hesitation or project execution challenges. - Hybrid vehicle battery customer commercialization start Oct-Nov 2026 - binary milestone initiating ESS demand phase-up; management projected late-2027 for full-scale ramp, validating staged volume trajectory underpinning electrolyte salts growth acceleration through FY28. ## Which stock lists is Tatva Chintan Pharma Chem on? Tatva Chintan Pharma Chem is not on any of our India lists this week. ## Is Tatva Chintan Pharma Chem profitable? Tatva Chintan Pharma Chem Ltd earned ₹21.0 Cr of net profit in the Sep 2026 quarter, +110.0% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹42.0 Cr. Over 8 years profit has grown 17.0% a year on average. That is 9.7% of the quarter's revenue. The same quarter a year earlier earned ₹10.0 Cr. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹42.0 Cr (+600.0% on the year before). Why profit moved: revenue changed +75.0% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +379.5% and revenue +48.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. FY27-Q1. revenue ₹167 Cr and profit ₹16 Cr as reported. FY27-Q2. revenue ₹217 Cr and profit ₹21 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## How much revenue does Tatva Chintan Pharma Chem make, and is it growing? Tatva Chintan Pharma Chem Ltd reported ₹217 Cr of revenue in the Sep 2026 quarter, +75.0% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 8 years it has grown 17.8% a year on average. The last full year, FY26, came in at ₹506 Cr. Why this happened. Tatva is transitioning its pharma pipeline into commercial production, with one molecule launched in the first quarter and two more planned later in the year. This new revenue stream carries higher margins due to chemical complexity and will utilize the newly commissioned Dahej capacity. The last four reported quarters add to ₹649 Cr. FY26 revenue was ₹506 Cr, +32.1% on the year before. Recent pace: the last four quarters grew +48.5% on average, against 17.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +49.2%, against +32.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +244.4%, against +91.0% a year (accelerating). FY27-Q1. revenue ₹167 Cr and profit ₹16 Cr as reported. FY27-Q2. revenue ₹217 Cr and profit ₹21 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## How much of every ₹100 of sales does Tatva Chintan Pharma Chem keep? Tatva Chintan Pharma Chem Ltd's operating margin was 19.0% in the Sep 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 9 years it has been between 9.0% and 25.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +0.7 percentage points on the year while gross margin changed −4.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged. FY27-Q1. revenue ₹167 Cr and profit ₹16 Cr as reported. FY27-Q2. revenue ₹217 Cr and profit ₹21 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## Is Tatva Chintan Pharma Chem's profit turning into cash? Over the last 3 years, 197% of Tatva Chintan Pharma Chem Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹31.0 Cr of operating cash against ₹42.0 Cr of profit. After ₹118 Cr of spending on assets, free cash was −₹87.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 197% of profit came in as cash: the cash cycle got 141 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 3.3× depreciation over three years. The next section checks what that spending is building. ## Where does Tatva Chintan Pharma Chem's cash go? Tatva Chintan Pharma Chem Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 310 days in FY26, up from 169 days in FY21. It spent ₹298 Cr on assets over the last 3 years. Customers take 86 days to pay, and stock sits for 319 days on average. Why this happened. The first commercial plant-scale batch for semiconductor applications was successfully qualified by the customer. While full commercialization requires additional trials, this validates the R&D capabilities and positions Tatva for a significant long-term growth vector. At FY26 sales of ₹506 Cr, each day of that cycle ties up about ₹1.4 Cr, so roughly ₹430 Cr is tied up in the business at any time. FY26: customers took 86 days to pay and stock sat for 319 days, about 10.5 months of sales sitting as stock, for a full cycle of 310 days, longer than FY21's 169. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 319 days. Customers pay about 86 days after that. Suppliers are paid at 95 days. Together that makes the 310-day cycle. Spending on assets: ₹298 Cr over the last 3 years, against ₹91.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹25.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Tatva Chintan Pharma Chem's P/E ratio, and how does it compare with its own history? Tatva Chintan Pharma Chem Ltd's P/E is 60.0×, near the low end of its own history: it has been lower only 25% of the time. Its usual P/E (the middle reading) is 77.7×, over 5.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹26.90. Why the multiple is where it is: over the past year earnings per share moved +636.9% while the price moved +15.1%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −10.5% a year; about +3.0% a year came from earnings growth and about −13.5 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Tatva Chintan Pharma Chem business getting better or worse? Tatva Chintan Pharma Chem Ltd's business is turning around. Profit growth has swung from −73.1% at its low to +244.4%, rising from a low 5 quarters ago, with ROCE steady at 3.5%. This is based on 12 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. ## What is the Tatva Chintan Pharma Chem story, and has it been checked? Tatva Chintan Pharma Chem Ltd's story is not scored yet against the checks our research set on 19 July 2026. Where it sits in its own cycle: Not stated in the research file. Still open: Inability to pass through raw material cost inflation to customers within an initial lag by the third quarter, leading to OPM remaining depressed. Our read, 19 July 2026. Capex commissioning and Pharma/Agro scale-up masking underlying margin improvement via optical high working capital phase. From the numbers. The business is in an early expansion phase with trailing earnings depressed by under-utilized capacity and launch-phase costs. From the price. Price stage 2, week 27, above its 200-day line, relative strength falling. From the research. Capex commissioning and Pharma/Agro scale-up masking underlying margin improvement via optical high working capital phase. Where they disagree. The business is in an early expansion phase with trailing earnings depressed by under-utilized capacity and launch-phase costs. What is proven. Capex commissioning and Pharma/Agro scale-up masking underlying margin improvement via optical high working capital phase. What is not proven yet. Inability to pass through raw material cost inflation to customers within an initial lag by the third quarter, leading to OPM remaining depressed. What would change our mind. Inability to pass through raw material cost inflation to customers within an initial lag by the third quarter, leading to OPM remaining depressed. The test written in advance. Inability to pass through raw material cost inflation to customers within an initial lag by the third quarter, leading to OPM remaining depressed. Measured by: the thesis as written as stated by the next result. The test written in advance. Raw Material Inflation. Measured by: Raw Material Inflation Gross margin percentage dropping significantly in subsequent quarters. by the next result. The test written in advance. Working Capital Drag. Measured by: Working Capital Drag Inventory days continuing to expand without proportional revenue growth. by the next result. What the company does. Tatva Chintan has transitioned from a pure Phase Transfer Catalyst (PTC) business to higher-margin pharma and agro intermediates, commissioning its Dahej block and initiating a greenfield Jolwa facility. Recent margin pressure stems from pricing lag and under-utilized capacity, but operating leverage will expand margins as peak pharma revenue commercializes. The ROE optical depression reflects the launch phase channel stocking and early utilization, which will mean-revert as volume absorption occurs. What the surface reading misses. The surface reading is: Margin is compressed relative to history. The research reads it further: Raw material inflation (amines up 30-40%) encountered a 40-50 day pass-through lag; margins will revert as pricing catches up and utilization increases. What the surface reading misses. The surface reading is: ROE indicates a low-quality or structurally impaired business. The research reads it further: ROE denominator (equity/assets) is inflated by recent capex commissioning and launch-phase inventory build, while the numerator (earnings) lags. This is an early-expansion optical distortion. Sources: our stock research file (19 July 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Tatva Chintan Pharma Chem management deliver what it promised? What Tatva Chintan Pharma Chem Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Greenfield Capex spending Revision · 17 July 2026. In the Jan 2026 call, management stated the first phase of the Jolva greenfield project would involve a capex of INR250-275 crores, with final drawings and estimation underway. Jolva Project Groundbreaking Timeline Shifts · 17 July 2026. Management stated in the May 2026 call that the groundbreaking for the Jolva project was expected within the quarter, with the timeline having been pushed back 4-6 weeks due to design optimization. SDA Capacity Utilization and Revenue Potential Contradiction · 17 July 2026. In the Jan 2026 call, management indicated SDA capacity utilization was at approximately 55% and that a 25-30% growth rate was expected, implying no need for major capex to support expansion. However, in the Jul 2026 call, management stated that beyond INR800-850 crores in total company revenue, new infrastructure would be needed, directly linking this constraint to SDA growth from the new Jolva facility, which contradicts the earlier statement that existing capacity was sufficient. SDA Segment Growth Revised Downward · 16 May 2026. Management lowered their growth guidance for the Structured Directing Agents (SDA) segment from the 25% to 30% range projected in the Jan 2026 call to a more conservative goal of at least 20% in the May 2026 call. This revision reflects growing caution due to geopolitical uncertainties that were previously viewed as manageable. Every quote above is taken word for word from the company’s own earnings calls. ## What is Tatva Chintan Pharma Chem management's track record? The current sweep found routine exchange filings but no company-specific enforcement or fraud action. 0% Promoter shares pledged

Sources:

- [trendlyne.com](https://trendlyne.com/research-reports/stock/596196/TATVA/tatva-chintan-pharma-chem-ltd/)
- [sharekhan.com](https://www.sharekhan.com/stock/tatva-chintan-pharma-chem-ltd/overview)
- [choiceindia.com](https://choiceindia.com/stocks/tatva-chintan-pharma-chem-ltd-shareholding-pattern)

(Checked 30 August 2026.)

## How much does Tatva Chintan Pharma Chem earn on its capital? Tatva Chintan Pharma Chem Ltd earned a ROCE of 7% in FY26. That is up from a low of 1% in FY25. Its return on capital used (ROIC) is 4.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 8.3% net margin and 0.50× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 8.3% net margin × 0.50× asset turnover × 1.29× leverage (assets divided by equity) ≈ 5.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 7.1% − 12.0% = −4.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 7.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 5.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Tatva Chintan Pharma Chem have too much debt? Tatva Chintan Pharma Chem Ltd has total debt of ₹170 Cr against shareholder equity of ₹815 Cr as of Sep 2026, so its debt is 0.21× its equity, which is very little. Year by year, that ratio went from 0.25 in FY22 to 0.15 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Tatva Chintan Pharma Chem shareholding pattern? Domestic institutions cut their stake in Tatva Chintan Pharma Chem Ltd by 3.6 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 3.2% of the company. Foreign institutions moved +1.0 points over the same period, to 4.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −3.6 points over 8 quarters, to 3.2%; Foreign institutions: +1.0 points over 8 quarters, to 4.4%; Promoters: +0.0 points over 8 quarters, to 72.0%. Why the owners changed: domestic institutions drove it (−3.6 points), with the other side taken by foreign institutions (+1.0 points). They reduced their stake. ## How far is Tatva Chintan Pharma Chem from balance-sheet trouble? For Tatva Chintan Pharma Chem Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Tatva Chintan Pharma Chem rank in its industry? 60.1 out of 100, rank 6 of 30 in Speciality Chemicals, with 93% of the evidence available. Tatva Chintan Pharma Chem Ltd scores 60.1 out of 100 against the 30 companies it is compared with in Speciality Chemicals, ranking 6. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 28.7 + 8.7 + 11.3 + 11.4 = 60.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Tatva Chintan Pharma Chem compared with? Tatva Chintan Pharma Chem ranks 6 of 30 Speciality Chemicals companies on the 4-Factor Sector Score, with 60.1 out of 100. 1. [Panama Petrochem Ltd](https://www.sectoralpha.in/stocks/panama-petrochem-ltd) PANAMAPET · turning · Sector-leading setup · 96% evidence 80.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.8/35 · Revenue 45.9% · Profit 100% · Operating margin change 14 points · 88% evidence Capital efficiency 15.9/25 · ROCE 19.2% · Operating margin 22% · 100% evidence Valuation 19.7/20 · P/E 5.7× · PEG 0.18 · 100% evidence Relative strength 13.9/20 · Lead over its industry 16.3% · Lead over NIFTY 500 31.3% · 1 year 68.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 30.8 + 15.9 + 19.7 + 13.9 = 80.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Yasho Industries Ltd](https://www.sectoralpha.in/stocks/yasho-industries-ltd) YASHO · losing its lead · Most evidence points up · 78% evidence 67.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.0/35 · Revenue 54.2% · Profit 100% · Operating margin change 3 points · 100% evidence Capital efficiency 12.3/25 · ROCE 8.9% · Operating margin 21% · 100% evidence Valuation 12.7/20 · P/E 45× · PEG 1.02 · 65% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 41.1% · 1 year 103.4% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30 + 12.3 + 12.7 + 12.2 = 67.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Vikram Thermo (India) Ltd](https://www.sectoralpha.in/stocks/vikram-thermo-indialtd) breaking out · Evidence leans up · 68% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 16.9% · Profit 41.9% · Operating margin change 8 points · 83% evidence Capital efficiency 21.3/25 · ROCE 36.2% · Operating margin 48% · 95% evidence Valuation 6.6/20 · P/E 25.8× · PEG n/a · 50% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 74.5% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 21.3 + 6.6 + 12.5 = 64.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Sunshield Chemicals Ltd](https://www.sectoralpha.in/stocks/sunshield-chemicals-ltd) SUNSHIEL · quiet · Evidence leans up · 81% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 12.9% · Profit 100% · Operating margin change 5 points · 88% evidence Capital efficiency 18.8/25 · ROCE 19.9% · Operating margin 16% · 100% evidence Valuation 10.8/20 · P/E 24.3× · PEG 2.21 · 100% evidence Relative strength 10.8/20 · Lead over its industry n/a · Lead over NIFTY 500 4.3% · 1 year -4% · 25% evidence · 0 of 5 weeks ahead Exact sum: 23.6 + 18.8 + 10.8 + 10.8 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Black Rose Industries Ltd](https://www.sectoralpha.in/stocks/black-rose-industries-ltd) BLACKROSE · quiet · Evidence leans up · 81% evidence 60.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 8.6% · Profit 28.6% · Operating margin change 6 points · 88% evidence Capital efficiency 16.4/25 · ROCE 18.7% · Operating margin 16% · 100% evidence Valuation 10.0/20 · P/E 17.1× · PEG 4.96 · 100% evidence Relative strength 10.9/20 · Lead over its industry n/a · Lead over NIFTY 500 4.4% · 1 year n/a · 25% evidence · 7 of 12 weeks ahead Exact sum: 23.6 + 16.4 + 10 + 10.9 = 60.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. Tatva Chintan Pharma Chem Ltd this page TATVA · losing its lead · Evidence leans up · 93% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 49.2% · Profit 100% · Operating margin change 1 points · 100% evidence Capital efficiency 8.7/25 · ROCE 7.2% · Operating margin 19% · 100% evidence Valuation 11.3/20 · P/E 60.2× · PEG 1.21 · 65% evidence Relative strength 11.4/20 · Lead over its industry 7.8% · Lead over NIFTY 500 23.3% · 1 year 15.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28.7 + 8.7 + 11.3 + 11.4 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Aether Industries Ltd](https://www.sectoralpha.in/stocks/aether-industries-ltd) AETHER · leader · Evidence leans up · 90% evidence 59.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 30.2% · Profit 28.4% · Operating margin change 1 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.9% · Operating margin 32% · 100% evidence Valuation 9.7/20 · P/E 85.1× · PEG n/a · 50% evidence Relative strength 14.8/20 · Lead over its industry 22.3% · Lead over NIFTY 500 38.6% · 1 year 114.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.4 + 12.8 + 9.7 + 14.8 = 59.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Privi Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/privi-speciality-chemicals-ltd) PRIVISCL · quiet · Evidence leans up · 82% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 17.5% · Profit 44.5% · Operating margin change -1 points · 95% evidence Capital efficiency 18.5/25 · ROCE 22.3% · Operating margin 26% · 76% evidence Valuation 10.1/20 · P/E 33.7× · PEG n/a · 50% evidence Relative strength 7.1/20 · Lead over its industry -9.7% · Lead over NIFTY 500 4.2% · 1 year 10.5% · 100% evidence · 2 of 12 weeks ahead Exact sum: 23.7 + 18.5 + 10.1 + 7.1 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Fineotex Chemical Ltd](https://www.sectoralpha.in/stocks/fineotex-chemical-ltd) FCL · leader · Evidence leans up · 96% evidence 59.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.3/35 · Revenue 91.5% · Profit 41% · Operating margin change -2 points · 88% evidence Capital efficiency 13.5/25 · ROCE 18.3% · Operating margin 16% · 100% evidence Valuation 5.7/20 · P/E 46.1× · PEG 1.92 · 100% evidence Relative strength 19.5/20 · Lead over its industry 34.1% · Lead over NIFTY 500 48.9% · 1 year 62.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.3 + 13.5 + 5.7 + 19.5 = 59 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [DMCC Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/dmcc-speciality-chemicals-ltd) DMCC · quiet · Evidence leans up · 93% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.9/35 · Revenue 72.1% · Profit 34.5% · Operating margin change -6.9 points · 100% evidence Capital efficiency 8.7/25 · ROCE 14.8% · Operating margin 4.2% · 100% evidence Valuation 16.1/20 · P/E 16.9× · PEG 0.44 · 65% evidence Relative strength 7.8/20 · Lead over its industry -12.3% · Lead over NIFTY 500 0.9% · 1 year -15.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 22.9 + 8.7 + 16.1 + 7.8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Aarti Industries Ltd](https://www.sectoralpha.in/stocks/aarti-industries-ltd) AARTIIND · quiet · Evidence leans up · 100% evidence 55.2 out of 100 Growth Capital Valuation Relative
12. [Galaxy Surfactants Ltd](https://www.sectoralpha.in/stocks/galaxy-surfactants-ltd) GALAXYSURF · leader · Evidence leans up · 81% evidence 53.9 out of 100 Growth Capital Valuation Relative
13. [Pidilite Industries Ltd](https://www.sectoralpha.in/stocks/pidilite-industries-ltd) PIDILITIND · quiet · Evidence leans up · 100% evidence 53.0 out of 100 Growth Capital Valuation Relative
14. [DIC India Ltd](https://www.sectoralpha.in/stocks/dic-india-ltd) DICIND · breaking out · Evidence leans up · 81% evidence 53.0 out of 100 Growth Capital Valuation Relative
15. [Kronox Lab Sciences Ltd](https://www.sectoralpha.in/stocks/kronox-lab-sciences-ltd) KRONOX · breaking out · Evidence leans up · 74% evidence 51.8 out of 100 Growth Capital Valuation Relative
16. [Neogen Chemicals Ltd](https://www.sectoralpha.in/stocks/neogen-chemicals-ltd) NEOGEN · leader · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative
17. [Chemcon Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/chemcon-speciality-chemicals-ltd) CHEMCON · breaking out · Evidence leans up · 85% evidence 51.1 out of 100 Growth Capital Valuation Relative
18. [Alkyl Amines Chemicals Ltd](https://www.sectoralpha.in/stocks/alkyl-amines-chemicals-ltd) ALKYLAMINE · quiet · Evidence leans down · 96% evidence 47.9 out of 100 Growth Capital Valuation Relative
19. [Grauer & Weil (India) Ltd](https://www.sectoralpha.in/stocks/grauer-weil-indialtd) GRAUWEIL · breaking out · Evidence leans down · 96% evidence 46.3 out of 100 Growth Capital Valuation Relative
20. [Paushak Ltd](https://www.sectoralpha.in/stocks/paushak-ltd) PAUSHAKLTD · losing its lead · Evidence leans down · 85% evidence 45.8 out of 100 Growth Capital Valuation Relative
21. [Innovassynth Technologies (India) Ltd](https://www.sectoralpha.in/stocks/innovassynth-technologies-indialtd) breaking out · Too little evidence to rank firmly · 53% evidence 44.0 out of 100 Growth Capital Valuation Relative
22. [Anupam Rasayan India Ltd](https://www.sectoralpha.in/stocks/anupam-rasayan-india-ltd) ANURAS · turning · Evidence leans down · 78% evidence 43.7 out of 100 Growth Capital Valuation Relative
23. [Platinum Industries Ltd](https://www.sectoralpha.in/stocks/platinum-industries-ltd) PLATIND · turning · Evidence leans down · 81% evidence 42.5 out of 100 Growth Capital Valuation Relative
24. [Vinati Organics Ltd](https://www.sectoralpha.in/stocks/vinati-organics-ltd) VINATIORGA · quiet · Evidence leans down · 82% evidence 42.4 out of 100 Growth Capital Valuation Relative
25. [Amal Ltd](https://www.sectoralpha.in/stocks/amal-ltd) AMAL · quiet · Evidence leans down · 68% evidence 41.5 out of 100 Growth Capital Valuation Relative
26. [Amines & Plasticizers Ltd](https://www.sectoralpha.in/stocks/amines-plasticizers-ltd) AMNPLST · quiet · Evidence leans down · 81% evidence 41.1 out of 100 Growth Capital Valuation Relative
27. [Transpek Industry Ltd](https://www.sectoralpha.in/stocks/transpek-industry-ltd) TRANSPEK · losing its lead · Evidence leans down · 63% evidence 38.6 out of 100 Growth Capital Valuation Relative
28. [Vishnu Chemicals Ltd](https://www.sectoralpha.in/stocks/vishnu-chemicals-ltd) VISHNU · losing its lead · Evidence leans down · 100% evidence 38.4 out of 100 Growth Capital Valuation Relative
29. [Clean Science & Technology Ltd](https://www.sectoralpha.in/stocks/clean-science-technology-ltd) CLEAN · breaking out · Evidence leans down · 85% evidence 38.1 out of 100 Growth Capital Valuation Relative
30. [Thirumalai Chemicals Ltd](https://www.sectoralpha.in/stocks/thirumalai-chemicals-ltd) TIRUMALCHM · quiet · Most evidence points down · 68% evidence 27.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Speciality Chemicals](https://www.sectoralpha.in/sectors/speciality-chemicals), all 30 compared on one page. ## Which companies are close to Tatva Chintan Pharma Chem in size? Tatva Chintan Pharma Chem is the 13th largest of 30 Speciality Chemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Neogen Chemicals, Fineotex Chemical and Yasho Industries. Just below it: Vishnu Chemicals, Grauer & Weil (India) and Panama Petrochem. ### Speciality Chemicals companies close in size

1. [Neogen Chemicals Ltd](https://www.sectoralpha.in/stocks/neogen-chemicals-ltd) ₹6,523 crore
2. [Fineotex Chemical Ltd](https://www.sectoralpha.in/stocks/fineotex-chemical-ltd) ₹5,635 crore
3. [Yasho Industries Ltd](https://www.sectoralpha.in/stocks/yasho-industries-ltd) ₹3,888 crore
4. Tatva Chintan Pharma Chem Ltd ₹3,845 crore
5. [Vishnu Chemicals Ltd](https://www.sectoralpha.in/stocks/vishnu-chemicals-ltd) ₹3,650 crore
6. [Grauer & Weil (India) Ltd](https://www.sectoralpha.in/stocks/grauer-weil-indialtd) ₹3,640 crore
7. [Panama Petrochem Ltd](https://www.sectoralpha.in/stocks/panama-petrochem-ltd) ₹2,726 crore

[All 30 Speciality Chemicals companies, largest first](https://www.sectoralpha.in/sectors/speciality-chemicals#all-companies)

### Companies close in size in other industries

1. [Orient Electric Ltd](https://www.sectoralpha.in/stocks/orient-electric-ltd) ₹3,854 crore · Consumer Electronics
2. [Share India Securities Ltd](https://www.sectoralpha.in/stocks/share-india-securities-ltd) ₹3,850 crore · Finance - Capital Markets - Brokers
3. Tatva Chintan Pharma Chem Ltd ₹3,845 crore
4. [DEE Development Engineers Ltd](https://www.sectoralpha.in/stocks/dee-development-engineers-ltd) ₹3,818 crore · Steel - Tubes/Pipes
5. [LCC Projects Ltd](https://www.sectoralpha.in/stocks/lcc-projects-ltd) ₹3,812 crore

## What else do people ask about Tatva Chintan Pharma Chem? ### What is Tatva Chintan Pharma Chem's share price today? Tatva Chintan Pharma Chem Ltd's share price is ₹1,637.10, +15.1% over the past year. The whole company is worth ₹3,829 Cr on the market. In the last 52 weeks it traded between ₹1,090 to ₹1,944; today it is 64% of the way up from the low, 11.0% above its 200-day average (as of 3 November 2026). ### What were Tatva Chintan Pharma Chem's latest quarterly results? Tatva Chintan Pharma Chem Ltd reported revenue of ₹217 Cr and net profit of ₹21.0 Cr for the Sep 2026 quarter. Revenue rose 75.0% and profit rose 110.0% compared with a year earlier. Earnings per share were ₹9.17 (as of 3 November 2026). ### What is Tatva Chintan Pharma Chem's market cap? Tatva Chintan Pharma Chem Ltd's market capitalisation is ₹3,829 Cr at a share price of ₹1,637.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Tatva Chintan Pharma Chem performing? Tatva Chintan Pharma Chem Ltd's share price has been rising for 27 weeks. In its latest quarter, revenue rose 75.0% and profit rose 110.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 3 November 2026). ### Will Tatva Chintan Pharma Chem's share price go up? This page does not forecast Tatva Chintan Pharma Chem Ltd's share price. What it shows instead: the share price is ₹1,637.10, and it has been rising for 27 weeks. Its P/E of 60.0× is higher than 25% of its own last 5 years (as of 3 November 2026). ### Who owns Tatva Chintan Pharma Chem? Promoters own 72.0% of Tatva Chintan Pharma Chem Ltd, foreign institutions 4.4%, domestic institutions 3.2% and the public 20.4% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 3.6 percentage points over 8 quarters (as of 3 November 2026). ### Does Tatva Chintan Pharma Chem have too much debt? No, Tatva Chintan Pharma Chem Ltd has little debt: its debt is 0.15× its equity, and its operating profit is 31 times its interest bill. FY26 borrowings were ₹120 Cr against equity of ₹781 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Tatva Chintan Pharma Chem in its business cycle? Tatva Chintan Pharma Chem Ltd's FY26 operating margin was 18.0%, against a 9-year range of 9.0% to 25.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 19.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Tatva Chintan Pharma Chem story? The main question: yearly earnings per share moved +636.9% while the share price moved +15.1%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Tatva Chintan Pharma Chem a stock worth studying right now? What the numbers show: Tatva Chintan Pharma Chem Ltd's results are improving, while its P/E is near the low end of its own history over 5.3 years, higher than only 25% of past readings. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Tatva Chintan Pharma Chem share price forecast for 2026? What management itself guided: FY27 consolidated revenue growth 25-30% with operating margin goal 20-22%. What is changing at Tatva Chintan Pharma Chem, from the latest results and calls: pharma commercialization ramp and semiconductor validation. What would change the story: Inability to pass through raw material cost inflation to customers within an initial lag by the third quarter, leading to operating margin remaining depressed. ### Where does this page get Tatva Chintan Pharma Chem's management information? From Tatva Chintan Pharma Chem's results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. This is research, not advice. We’re not SEBI-registered.